logo.jpg
Clariant returns to profitable growth, increasing both sales and profitability in the first quarter of 2021
April 29, 2021 01:00 ET | Clariant AG
Sales from continuing operations increased by 2 % in local currency to CHF 1.002 billion, reflecting a broad recovery in our markets EBITDA of CHF 164 million rose by 4 % in Swiss francs, generating a...
logo.jpg
Clariant delivers robust performance in 2020, successfully mitigating COVID-19 pandemic impacts
February 11, 2021 01:00 ET | Clariant AG
Sales from continuing operations decreased by 5 % in local currency to CHF 3.860 billion EBITDA margin preserved at 15.0 % in a challenging environment compared to a comparable EBITDA margin of 15.7 %...
Delårsrapport 3 2020 januari - september 2020
November 19, 2020 02:30 ET | Northbaze Group AB
Q3 2020 1 juli – 30 september 2020 i korthet Northbaze Group uppnår under det tredje kvartalet en nettoomsättning i nivå med föregående års tredje kvartal med ett positiv EBITDA resultat....
Clariant improves profitability in the first half of 2020 despite a difficult economic environment
July 30, 2020 01:00 ET | Clariant AG
Sales from continuing operations decreased by 5 % in local currency to CHF 1.945 billionEBITDA margin improved to 15.0 % compared to an operational performance of 14.9 % in the first half of 2019 Net...
Delårsrapport 1 2020 januari - mars 2020
April 28, 2020 02:30 ET | Northbaze Group AB
Q1 2020 1 januari – 31 mars 2020 i korthet Northbaze Group ökar sin nettoomsättning med 27 % under årets första kvartal i jämförelse med föregående års första kvartal. Omsättningen inom affärsområdet...
Boise Paper_Color_PCA.png
How to Select Office Paper that Impacts Productivity, Profitability in 2020
January 14, 2020 09:00 ET | Boise Paper Holdings LLC
CHICAGO, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Office paper may seem like a small expense to many people, but business owners know it can directly impact their productivity and profitability. As small...
download-2.png
Les résultats financiers d'Emerald Health Therapeutics au deuxième trimestre 2019 indiquent un doublement des ventes pour le deuxième trimestre consécutif
August 30, 2019 05:10 ET | Emerald Health Therapeutics Inc.
VANCOUVER, Colombie-Britannique, 30 août 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV : EMH ; OTCQX : EMHTF) a communiqué aujourd'hui ses résultats financiers...
download-2.png
Emerald Health Therapeutics Reports Second Quarter 2019 Financial Results; Sales Double Second Quarter in a Row
August 29, 2019 07:00 ET | Emerald Health Therapeutics Inc.
VANCOUVER, British Columbia, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) today reported financial results for the quarter ended June 30,...
download-2.png
La coentreprise Pure Sunfarms d'Emerald Health Therapeutics a réalisé un chiffre d'affaires de 32 millions $ au deuxième trimestre, une marge d'EBITDA de 78 %, un coût de production global de 0,65 $/g et un troisième trimestre de rentabilité consécutif
August 13, 2019 11:32 ET | Emerald Health Therapeutics Inc.
VICTORIA, Colombie-Britannique, 13 août 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV: EMH, OTCQX: EMHTF) a publié des résultats financiers préliminaires non...
download-2.png
Emerald Health Therapeutics’ Pure Sunfarms JV Reaches Q2 Sales of $32 Million, 78% EBITDA Margin, $0.65/Gram All-in Production Cost, and Third Consecutive Quarter of Profitability
August 13, 2019 00:19 ET | Emerald Health Therapeutics Inc.
VICTORIA, British Columbia, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) has provided preliminary, unaudited financial results for the...